Glucagon-like peptide-1 receptor agonists and the risk of cardiovascular events in diabetes patients surviving an acute myocardial infarction

AIMS: Trial evidence indicates that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may reduce the risk of cardiovascular (CV) events in patients with diabetes and myocardial infarction (MI). We aimed to expand this observation to routine care settings. METHODS AND RESULTS: Prospective observa...

Descripción completa

Detalles Bibliográficos
Autores principales: Trevisan, Marco, Fu, Edouard L, Szummer, Karolina, Norhammar, Anna, Lundman, Pia, Wanner, Christoph, Sjölander, Arvid, Jernberg, Tomas, Carrero, Juan Jesus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957901/
https://www.ncbi.nlm.nih.gov/pubmed/31999317
http://dx.doi.org/10.1093/ehjcvp/pvaa004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957901/
https://www.ncbi.nlm.nih.gov/pubmed/31999317
http://dx.doi.org/10.1093/ehjcvp/pvaa004

Ejemplares similares